5 completed, 2 terminated, 2 unknown, 1 recruiting. 4 Phase 3, 2 Phase 2, 2 Phase 4, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Unknown 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow SARS-CoV-2 inactivated vaccines: new trials by email Literature Review of SARS-CoV-2 inactivated vaccines trials Research Report on SARS-CoV-2 inactivated vaccines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation Pneumonia vaccine - Pneumococcal Vaccine, Esophageal Cancer | Recruiting | M.D. Anderson Cancer Center | 80 | 2024-02-05 | 2026-05-20 | |
| Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile CoronaVac®, Omicron Vaccine, Trivalent Vaccine - COVID-19, Vaccines | Phase 2 | Completed | Pontificia Universidad Catolica de Chile | 551 | 2022-11-28 | 2024-02-07 |
| Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine - COVID-19 | Early Phase 1 | Terminated | Binhui Biopharmaceutical Co., Ltd. | 80 | 2022-07-13 | 2025-07-28 |
| Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine Aerosolized Ad5-nCoV, Inactivated SARS-CoV-2 vaccine - COVID-19 | Phase 3 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 10285 | 2022-01-22 | 2025-02-21 |
| Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2, Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2 - COVID-19 | Phase 4 | Unknown | Sinovac Research and Development Co., Ltd. | 2520 | 2021-07-27 | 2023-11-07 |
| Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults Inactivated SARS-CoV-2 Vaccine (Vero cell） - COVID-19 | Phase 4 | Completed | Sinovac Research and Development Co., Ltd. | 1080 | 2021-05-11 | 2022-04-13 |
| The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 Inactivated SARS-CoV-2 Vaccine (Vero cell), Placebo - COVID-19 | Phase 3 | Unknown | Chinese Academy of Medical Sciences | 34020 | 2021-01-28 | 2021-02-10 |
| Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) Inactivated SARS-CoV-2 vaccine (Vero cell), Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine - COVID-19 Virus Infection | Phase 3 | Completed | Laboratorio Elea Phoenix S.A. | 3000 | 2020-09-16 | 2022-01-12 |
| A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above Inactivated SARS-CoV-2 Vaccine (Vero cell), Placebo - COVID-19 | Phase 3 | Completed | China National Biotec Group Company Limited | 44101 | 2020-07-16 | 2023-06-18 |
| Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) Lenalidomide, Influenza Vaccine, Pneumovax Vaccine - Hematologic Disorder | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2014-11-24 | 2018-09-20 |
COVID-19 (8) · Agammaglobulinemia (1) · Coronavirus Infections (1) · Esophageal Neoplasms (1) · Hematologic Diseases (1) · Influenza, Human (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphopenia (1)
M.D. Anderson Cancer Center (2) · Sinovac Research and Development Co., Ltd. (2) · Binhui Biopharmaceutical Co., Ltd. (1) · China National Biotec Group Company Limited (1) · Chinese Academy of Medical Sciences (1) · Jiangsu Province Centers for Disease Control and Prevention (1) · Laboratorio Elea Phoenix S.A. (1) · Pontificia Universidad Catolica de Chile (1)
China (4) · United States (2) · Argentina (1) · Bahrain (1) · Brazil (1) · Chile (1) · Egypt (1) · Jordan (1) · Malaysia (1) · United Arab Emirates (1)
Adilson JW Cavalcante, PhD (1) · Alessandra Ferrajoli, MD,BS (1) · Alexis M Kalergis, PhD (1) · Fengcai Zhu, Prof (1) · Hongxing Pan, Master (1) · Katia Abarca, MD (1) · Pablo A Gonzalez, PhD (1) · Steven H Lin, MD (1) · Susan M Bueno, PhD (1) · Walid A Zaher, MD, MSc,PhD (1) · Weijun Hu, Master (1)
PMID 34037666, PMID 35464483, PMID 36441137, PMID 36851177, PMID 37352880, PMID 41398275